🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Shares

Ex-drug CEO Shkreli asks U.S.court to consider blocking subpoena

Published 23/01/2016, 19:21
© Reuters. File photo of Shkreli, chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, departing U.S. Federal Court in New York

By David Ingram

NEW YORK (Reuters) - Lawyers for former pharmaceuticals executive Martin Shkreli have asked a U.S. federal judge for guidance on a demand by lawmakers that Shkreli appear at a hearing on Tuesday, writing that if travel restrictions on him are not lifted, the congressional subpoena should be blocked.

Lawyers for Shkreli sent a letter to U.S. District Judge Kiyo Matsumoto in Brooklyn late on Friday laying out the conflict between them and the U.S. House Committee on Oversight and Government Reform over Shkreli's attendance.

Shkreli, 32, stepped down last month as chief executive of Turing Pharmaceuticals Inc after his arrest on securities fraud charges.

The Oversight Committee says it wants to hear testimony from Shkreli about Turing's decision to raise the price of lifesaving medicine Daraprim by more than 5,000 percent. Shkreli says he should be excused from going to Washington because he plans to invoke his right against self-incrimination and refuse to answer questions.

Under his conditions for pre-trial release, Shkreli is also required to remain in parts of New York state, although he could ask for a travel waiver.

If he does not appear at the hearing, though, lawmakers have threatened to seek criminal contempt charges against him.

The letter on Friday did not ask for a travel waiver for Shkreli, but the lawyers wrote that if Shkreli "may not leave" New York, "then we respectfully request that the court accept this letter as a motion to quash or to stay the subpoena."

A committee spokeswoman could not immediately be reached for comment on Saturday.

© Reuters. File photo of Shkreli, chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, departing U.S. Federal Court in New York

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.